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Sa.ry We have measured bone mineral density (BMD) in 29 men, mean age 35.0 (range 19.7-58.0) years,
with testicular damage following MVPP or hybrid chemotherapy for Hodgkin's diseas. Forearm cortical bone
mineral content (BMC) and lumbar spie and femoral neck integral BMD were measured 3.4 (1.1-6.8) years
after completion of chemotherapy, and results expressd as Z (standard deviation) scores. There was a
significant reduction in forearm corfical BMC (mxdian BMC 1.727 gcm-', median Z-score - 0.8,
P <0.0005), in hlmbar spine integra BMD (median BMD 1.141 gcm-2, Median Z-score - 0.6, P<0.0005)
and in femoral neck integral BMD (median BMD 0.991 gcM-2, medi Z-score -0.4, P<0.05). There was
no significant correlation betwen Z-score and time elapsed since completion of chemotherapy, and no
signifkcant difference in Z-score according to type of chemotherapeutic rimen or number of cycles of
chemotherapy reived. In conchlsion, men who are in complete remsson following treatment of Hodgkin's
disease have reduced corfical and trabecular BMD. Possible causes incude mild hypogonadism secondary to
chemotherapy-induced impairment of Leydig cell function, a direct effect of chemotherapy on bone, an effect
of high-dose ghuocorticid on bone or an effect of Hodgkin's disease per se.
It is well established that hypogonadism in either sex is
associated with a reduction in bone mineral density (BMD).
Causes of hypogonadal osteoporosis in men include idio-
pathic hypogonadotrophic hypogonadism (Finkeistein et al.,
1987), hyperprolactinaemia (Greenspan et al., 1986) and
Klinefelter's syndrome (Horowitz et al., 1992), resulting in a
reduction in both cortical and trabecular BMD. Men with a
history of delayed puberty, who are effectively androgen
deficient at a critical stage in their attainnt of peak bone
mass, have reduced cortical and trabecular BMD (Finkelstein
et al., 1992). Men who undergo bilateral orchidectomy have
a rapid and progressive loss of lumbar spine integral bone
with time from orchidectomy (Stepan et al., 1989). In men
with hyperprolactinaemic hypogonadism restoration of nor-
mal testicular function is assocated with a significant in-
crease in cortical BMD (Greenspan et al., 1986). Siilarly,
restoration of normal serum testosterone in men with
idiopathic hypogonadotrophic hypogonadism is also associa-
ted with a significant increase in cortical BMD (Finkelstein et
al., 1989).
Men who receive conventional chemotherapy with mustine,
vinblastine or vincristine, procarbazine and prednisolone for
treatment of Hodgkin's disease become azoospermic with
raised serum follicle-stimulating hormone (FSH) levels, indi-
cating chemotherapy-induced damage to the germinal epithe-
lium (Whitehead et al., 1982; Tsatsoulis et al., 1987). Leydig
cell function is more difficult to categorise. The serum testos-
terone level and free testosterone index have been shown to
be normal (Tsatsoulis et al., 1987), but the serum luteinising
hormone (LH) concentration is raised, suggesting a subtle
form of Leydig cell dysfunction (Whitehead et al., 1982;
Tsatsoulis et al., 1987). However, testosterone response to a
large bolus dose of human chorionic gonadotrophin (hCG)
was found to be normal (Tsatsoulis et al., 1987).
Kreuser et al. (1992) studied BMD in men and women
who had received chemotherapy, with or without additional
radiotherapy, for treatment of Hodgkin's disease 2-10 years
previously. In men, serum testosterone was normal at the
time of BMD measurement, and there was no signifcant
reduction in cortical or trabecular BMD mesured using
single photon absorptiometry (SPA) and quantitative com-
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puted tomography. There was, however, a significant reduc-
tion in cortical and trabecular BMD in women with
chemotherapy-induced premature ovarian failure compared
with similarly treated women with normal ovarian function.
We have studied BMD in 29 men in complete remission
following treatment of Hodgkin's disease. We have studied
the relationship between serum testosterone and BMD, and
the effect on BMD of time elapsed since completion of
chemotherapy, type ofchemotherapy received and number of
cycles of chemotherapy.
S and methods
We studied 29 caucasian men who had previously received
chemotherapy for Hodg9in's disease. The study subjects were
drawn from 50 consecutive men who presented to the
Medical Oncology Dertment at Christie Hospital with
newly diagosed Hodgkin's diseas and who were ran-
domised to receive MVPP or hybrid chemotherapy. The 50
men took part in a study investigating the effects of MVPP
and hybrid chemotherapy on gonadal function, and 29 of
these men consented to have measurements of BMD per-
formed. In the 29 men who underwent measurements of
BMD, age at onset ofchemotherapy was 31.0 ± 1.9 (mean +
standard error, range 16.4-54.0) years. Twelve men had
received a mean of 7.5 (range 5-8) cycles of MVPP (mustine
10mgi.v. and vinblasin 10 mg i.v. on days 1 and 8 with
procarbazine 150mg daily and prednisolone 50mg daily on
days 1-14 of a 42 day cycle) and 17 men had received a
mean of 7.5 (range 6-8) cycles of hybrid chemotherapy
(vinblastine lOmgi.v. on day 1, with chlorambucil 1Omg
daily, procarbazine 150 mg daily and prednisolone 50 mg
daily on days 1-7, and etoposide 200mgm-2 i.v., viris
2mg i.v. and doxorubicin 50 mgm-2i.v. on day 8 of a 28
day cycle). Twenty-four men received radiotherapy (15 to
chest and mediastinum, eight to neck and one to axilla) but
none in a radiation field which included the testes or the
parts of the skeleton studied. All men were in complete
remission at the time of study, and all had azoospermia.
Blood samples were taken for estimation of serum tes-
tosterone, sex hormone-binding globulin (SHBG), LH and
FSH. Seven men had blood samples taken on one occasion,
19 on two occasions and three on three occasions. There
were therefore a total of 54 blood samples taken 2.7 ± 0.2
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(range 0.1 to 6.8) years after completion ofchemotherapy. In
the 22 men who had more than one blood sample taken, the
samples were taken 1.6 ± 0.1 (range 0.7-2.2) years apart.
Routine radioimmunoassays were used to perform these
measurements.
BMD measurements were performed 3.4 ± 0.3 (range 1.1
to 6.8) years after completion of chemotherapy at age
35.0 ± 2.0 (range 19.7-58.0) years. At the time of measure-
ment weight was 76.4 ± 2.5 (range 54.0-112.0) kg, height
1.77 ± 0.01 (range 1.64-2.00) m and body mass index
24.3 0.7 (range 17.8-34.2) kg m2.
The study was approved by the South Manchester Area
Health Authority Ethics Committee.
Bone densitometry
Single photon absorptiometry Bone mineral measurement
was performed by SPA in the non-dominant forearm using a
Nuclear Data NDIOOA scanner with an "2I radionuclide
source (Wahner et al., 1977). Scanning was performed at two
sites: ultradistal, giving a measure of integral bone, and
proximal, giving a measure of cortical bone. Data from only
the proximal site were used in the study. Bone mineral
content (BMC) was measured in gcm-. The precision of
BMC measurement in our department by SPA at the prox-
imal site is 1%.
SPA provides a measure of bone mineral per unit length of
forearm bones but takes no account of the width or depth of
the bone. Thomsen et al. (1986) have shown that BMC/lean
body mass (LBM) is an effective correction for both height
and weight. LBM was caculated according to the equation
of Boddy et al. (1972) and has previously been shown to fit
closely with LBM measured by dual photon absorptiometry
(Gotfredsen et al., 1986). We used both BMC and BMC/
LBM measurements in the men studied.
Dual energy X-ray absorptometry (DXA) Measurement of
integral (cortical and trabecular) bone was made in the lum-
bar spine (L2-L4) and the right femoral neck using a Lunar
DPX-L scanner (Lunar Corporation, Madison, WI, USA)
(Cullum et al., 1989). Mean BMD was measured in gcMn2.
Precision of the measurement in our department is 0.5% in
the spine and 2.5% in the femoral neck.
To assess whether the measurements made in each individ-
ual were normal or reduced, the values were expressed as Z
(standard deviation) scores (Parfitt, 1990) compared with
appropriate normal reference data matched for age and sex.
The DXA Z-scores were also weight corrected. The data
published by Thomsen et al. (1986) were used for SPA, and
data provided by the manufacturer (Lunar Corporation)
(Laskey et al., 1992) were used for DXA. These published
reference data were confirmed to be appropriate for men
from our local population using data derived from a study in
which individuals were drawn at random from the age and
sex register of a local medical practice and had BMD
measurements performed (Adams et al., 1992). If our local
reference group were exactly compatible with published
reference data they would have a mean Z-score of 0 with a
standard deviation (s.d.) of 1. Comparison of mean Z-scores
for published and local reference BMD was: SPA - 0.205
(s.d. 0.925), DXA lumbar spine 0.189 (s.d. 1.03) and DXA
femoral neck 0.205 (s.d. 0.%5).
Statistics
Comparisons of BMD with age- and sex-matched reference
data (results expressed as Z-scores) were performed using the
Wilcoxon matched-pairs signed-rankl test. Comparisons of
Z-scores between two subgoups of men were performed
using the Mann-Whitney U-test. Correlations between BMD
measurements and other variables are expressed as Spear-
man's correlation coefficients (r). A binomial test was used to
detect any change in serum testosterone, SHBG, LH and
FSH with time from completion of chemotherapy in those
men who had these measurements performed on more than
one occasion. A P-value of less than 0.05 was considered
statistically significant.
Results
There was a highly significant reduction in forearm cortical
BMC (SPA: median BMC 1.727gcm-1, median Z-score
- 0.8, range - 1.8 to + 1.3, P<0.0005), in forearm cortical
BMC/LBM (SPA: median BMC/LBM 0.917gcmn1kg-',
median Z-score - 0.7, range - 3.0 to + 2.1, P<0.005), and
in integral bone of the lumbar spine (DXA: median BMD
1.141 gcm2, median Z-score -0.6, range -1.7 to + 1.3,
P<0.0005) and a significant reduction in integral bone of
the femoral neck (DXA: median BMD 0.991 gcm-2, median
Z-score -0.4, range -2.1 to + 1.3, P<0.05). Results of
BMD measuurements are shown in Table I and illustrated as
individual Z-scores in Figure 1. There was no significant
correlation between time elapsed since completion of
chemotherapy and Z-score at any site.
There was no significant change in serum testosterone,
SHBG, LH and FSH with time from completion of chemo-
therapy in the 22 men who had these measurements per-
formed on more than one occasion, so the mean of these
measurements was used in these men, with the single
measurements used in the remaining seven men. Serum tes-
tosterone was 15.2 ± 1.1 (range 8.2-35.4) umol 1-' (normal
range 10-30 nmol1-1), serum SHBG 38.2 ± 2.1 (range 16.0-
70.5) umol 1' (normal range 10-50 nmol 1'), serum LH
9.7 ± 0.7 (range 5.0-19.0) IU 1' (normal range 2.0-10.0 IU
1-') and serum FSH 18.1 ± 1.6 IU 1-' (range 6.5-39.5) IU 1-'
(normal range 1.0-5.0 IU 1`). The results of serum tes-
tosterone, SHBG, LH and FSH are illustrated in Figure 2.
Results were also expressed as serum testosterone/SHBG
ratio (0.4 ± 0.0, range 0.2-0.7).
There was a significant positive correlation between serum
testosterone and Z-score of lumbar spine BMD (r= 0.37,
P=0.02) and of femoral neck BMD (r=0.41, P<0.02).
There was a significant negative correlation between serum
testosterone and Z-score of forearm BMC (r=-0.45,
P<0.01) but a non-significant positive correlation between
serum testosterone and Z-score of forearm BMC/LBM
(r=0.21, P=0.14). There was no significant correlation
between Z-score at any site and serum SHBG, LH or FSH.
There was a significant positive correlation between serum
testosterone/SHBG ratio and Z-score of femoral neck BMD
(r= 0.44, P<0.01) and a significant negative correlation
between serum testosterone/SHBG ratio and Z-score of
forearm BMC (r = -0.31, P<0.05). There was no signifi-
cant correlation between this ratio and Z-score of lumbar
spine BMD or of forearm BMC/LBM.
There was no significant difference in Z-score at any site
between those men who had received MVPP (n = 12) and
those who had received hybrid (n = 17) chemotherapy.
There was no significant difference in Z-score at any site
between those men who had received eight cycles (n = 20)
and those who had received 5-7 cycles (n = 9) of chemo-
therapy.
Dbcsiom
We have demonstrated a significant reduction in BMD in
men who have previously received chemotherapy for Hodg-
kin's disease. The reduction in BMD affects both cortical
bone, measured as the forearm by SPA, and integral bone,
measured at lumbar spine and femoral neck by DXA.
Measurements of BMD performed in men from our local
population have been confirmed to correspond well with
published reference data, indicating that expressing the BMD
measurements as Z-scores derived from these published
reference data is appropriate. We therefore feel that the
reduced BMD demonstrated at the three sites is a true obser-
vation, although it is not in accordance with the findings of
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TAe I Bone mineral density measurements and Z scores
DXA DXA
SPAI SPAI DXA DXA femoral femoral
SPA SPA LBM LBM L2-L4 L2-L4 neck neck
Patient (g cm-') Z-score (gcn-'kg-') Z-score (gCm-2) Z-score (gcn-2) Z-score
1 1.680 - 1.5 0.900 - 0.8 1.163 - 0.5 1.125 0.2
2 1.941 0.2 0.910 - 0.9 1.049 - 1.4 0.789 - 2.1
3 1.595 - 1.7 0.888 - 1.0 0.921 - 1.7 1.088 0.3
4 1.885 0.0 0.944 -0.6 1.145 -0.8 0.901 - 1.2
5 2.134 0.4 1.043 0.4 1.466 1.3 1.105 0.0
6 1.585 - 1.7 0.916 - 0.7 1.157 - 0.2 0.985 - 0.4
7 1.648 - 1.4 0.835 - 1.4 1.281 0.2 1.129 0.5
8 1.641 - 1.4 1.014 0.1 1.108 - 0.3 0.828 - 1.5
9 1.759 - 0.8 0.919 - 0.7 1.217 - 0.2 0.942 - 1.0
10 1.582 -1.3 0.831 - 1.5 1.139 - 0.5 0.936 - 0.4
11 1.727 -0.1 0.659 -3.0 1.215 -0.8 0.847 - 1.5
12 1.750 - 0.8 0.756 - 2.1 1.148 - 1.3 1.061 - 0.6
13 1.816 - 0.6 0.990 - 0.1 1.103 - 0.6 0.869 - 1.4
14 1.720 - 0.8 0.974 - 0.3 1.044 - 1.0 1.029 0.3
15 1.661 -0.8 0.900 -0.9 1.234 0.0 0.881 - 1.1
16 1.601 - 1.8 1.257 2.1 1.046 - 0.9 1.050 - 0.2
17 1.664 - 0.8 0.912 - 0.8 1.036 - 1.1 0.892 - 1.0
18 1.802 - 0.9 0.971 - 0.3 1.327 0.7 1.183 0.9
19 1.799 - 0.3 0.758 - 2.1 1.231 - 0.8 0.991 - 0.7
20 2.184 0.8 1.180 1.5 1.146 - 0.5 1.223 1.3
21 2.240 1.3 1.077 0.5 1.141 - 0.8 0.991 - 0.5
22 1.602 - 0.6 0.826 - 1.6 1.085 - 0.8 0.927 - 0.3
23 1.862 - 0.2 0.939 - 0.6 1.139 - 0.7 1.078 0.2
24 1.727 - 0.7 0.930 - 0.7 1.044 - 1.2 1.053 0.1
25 1.628 -0.8 0.788 - 1.9 1.137 -0.8 0.832 - 1.6
26 1.861 - 0.4 0.906 - 0.8 1.150 - 0.6 0.908 - 1.3
27 1.849 - 0.8 0.974 - 0.2 1.131 - 0.6 1.110 0.2
28 1.480 - 1.7 0.830 - 1.5 1.274 0.4 1.229 1.6
29 1.828 -0.8 1.083 0.7 1.081 -0.6 0.931 - 1.0
SPA, single photon absorptiometryq, LBM, lean body mass; DXA, dual energy X-ray absorpiiometry.
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received similar therapy for treatment of Hodgkin's disease
showed no evidence of osteopenia.
T1he signnt positive correlation between serum tes-
tosterone and Z-score at lumbar spine and femoral neck
suggests that a reduction in serum testosterone, which may
F1me 2 Serum testosterone, SHBG, LH and FSH.
be a consequence of chemotherapy-induced Leydig cell
damage, is associated with a reduction in integral BMD.
Serum LH was elevated in 13 of the 29 (45%) men studied,
in agreement with previous documentation of raised serum
LH levels following chemotherapy for treatment of Hodg-
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kin's disaw (Whitehead et al., 1982; Tsatsoulis et al., 1987),
indicating that Leydig cell function had been compromised in
at least some of the men studied. The well-established
association of hypogonadism and reduced BMD would sup-
port the possibility that subtle impairment of Leydig cell
function, and hence a possible degree of mild hypogonadism,
could result in a reduction of BMD. However, this mech-
anism does not explain the significant reduction in forearm
corucal BMC demonstrated in the men studied as there is a
significant negative correlation between serum testosterone
and Z-score at this site. It is possible that integral and
cortical bone may respond differently to hypogonadism of
varying severity, or to alternative adverse factors, as demon-
strated by the significnt reduction in forearm cortical BMC,
but lack of reduction in lumbar spine or femoral neck integ-
ral BMD, in women who had retained normal menstrual
function following treatment of Hodgkin's disease (Redman
et al., 1988). In these women the reduction in cortical bone
mass appears to be independent of chemotherapy-induced
impairment of ovarian function and hence hypogonadism.
The reduction of integral BMD in addition to cortical BMC
in women with premature ovarian failure following treatment
of Hodgkin's disease (Redman et al., 1988) suggests that the
reduced integral BMD is due to hypogonadism. However,
the possibility that cortical and integral bone respond
differently to hypogonadism is not in agreement with the
finding that both cortical and integral BMD are reduced in
men with severe hypogonadism due to idiopathic hypogon-
adotrophic hypogonadism (Finkelsstein et al., 1987) or hyper-
prolaminaemia (Greenspan et al., 1986). Furthemore, if the
osteopenia that we have demonstrated was due to hypogona-
dism, it might be expected that BMD would be further
reduced with increasing time elapsed since completion of
chemotherapy, and hence a longer duration of hypogona-
dism, but this is not the case in the men studied.
BMC, measured by SPA, provides a measure of bone
mineral per unit length of forearm bones only, and takes no
account of the width or depth of the bone; BMC/LBM can
be used to provide an effective correction for both height and
weight (Thomsen et al., 1986). The significant negative cor-
relation between serum testosterone and Z-score of forearm
cortical BMC, in contrast to the significant positive correla-
ton between serum testosterone and Z-score of lumbar spine
and femoral neck integral BMD, may be due to a confound-
ing effect of the size of the subject on the forearm cortical
BMC. This is supported by the finding of a positive (but
non-significant) correlation between serum testosterone and
forearm cortical BMC when corrected for LBM, in accor-
dance with the direction of the correlation between serum
testosterone and Z-score at lumbar spine and femoral neck.
This change in direction of the correlation from negative to
positive when BMC is corrected for LBM may be due to the
rather surprising and unexplained significant negative cor-
relation between serum testosterone and LBM (r =-0.36,
P<0.05).
Short-term treatment of rats with methotrexate and doxo-
rubicin has been shown to cause a significant reduction in
vertebral trabecular bone volume and in bone formation rate
(Friedlaender et al., 1984), raising the possibility that
chemotherapeutic agents may have a direct effect on bone
turnover, and hence BMD, in man. Furthermore, glucocor-
ticoid treatment can cause osteopenia (Baylink. 1983), and
the steroid component of the chemotherapeutic regimens
could be considered as a possible cause of osteopenia.
In conclusion, we have demonstrated that men who have
received chemotherapy for Hodgkin's disease have reduced
BMD. Possible causes include mild hypogonadism secondary
to impaired Leydig cell function following chemotherapy, a
direct effect of chemotherapy on bone, an effect of adminis-
tration ofhigh-dose glucocorticoid, or an effect of Hodgkin's
disease per se. A reduction in femoral neck BMD by one
standard deviation from the age-adjusted mean has been
shown to increase the risk of hip fracture by a factor of 2.6
in women over the age of 65 years (Cummings et al., 1993).
Our findings demonstrate that men who have received
chemotherapy for Hodgkin's disease may be at increased risk
of bone fracture in later life, irrespective of the aetiology of
the osteopenia.
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